Q-omics provides the consensus-scored HTR1F profile across patient tissues and cancer cell-line models. HTR1F expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, HTR1F is differentially expressed in 14, with the highest sampling consensus in KIRC. Additionally, HTR1F RNA expression shows 15,656 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KIRP, KIRC, and THYM as cancer lineages where HTR1F shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for HTR1F — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes HTR1F survival associations across molecular data types. HTR1F RNA expression shows survival associations in the most cancer types (22), followed by mutation status (9). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible HTR1F RNA expression–survival associations across cancer types. High HTR1F expression shows unfavorable associations in KIRP, UVM, STAD, LAML and MESO, but favorable associations in HNSC. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for HTR1F RNA expression.
This table summarizes HTR1F tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for HTR1F. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. HTR1F shows lower tumor expression in LUSC and KICH and higher tumor expression in KIRC, HNSC, LIHC and THCA. The KIRC box plot shows higher HTR1F RNA expression in tumor versus normal tissue (log2 FC = +0.928, t-test p < 0.001).
This table shows molecular features associated with HTR1F in patient tissues and cancer cell lines. In patient samples, HTR1F shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, HTR1F RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LIVER, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and LARGE_INTESTINE.
